COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Corporate Update on Clinical Evaluation of MedMira’s Products
MedMira Inc. provides update on Health Canada review process for maternity screening, highlighting increasing need due to rising syphilis infection rates. Company's syphilis test performance shows promising results for infectious case detection and maternity screening -
COMMUNIQUÉ DE PRESSE
MedMira Reports First Quarter Results FY2024
MedMira Inc. (TSXV:MIR) has reported its financial results for the quarter ended October 31, 2023. The company achieved significant milestones during this period, including receiving US FDA 510(k) clearance for the HIV-2 claim on its Reveal® G4 Rapid HIV 1/2 antibody test. This approval positions MedMira as a key player in the HIV testing market and allows the company to expand its market share and revenue in the United States. -
COMMUNIQUÉ DE PRESSE
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
-
COMMUNIQUÉ DE PRESSE
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
-
COMMUNIQUÉ DE PRESSE
Update on MedMira’s Regulatory Path in Canada and the USA
-
COMMUNIQUÉ DE PRESSE
Progress Update on Securities
-
COMMUNIQUÉ DE PRESSE
MedMira Reports Third Quarter Results FY2023
-
COMMUNIQUÉ DE PRESSE
MedMira Reports Second Quarter Results FY2023
-
COMMUNIQUÉ DE PRESSE
Update on MedMira’s Reveal TP (Syphilis) Clinical Trials in Canada
